524 related articles for article (PubMed ID: 30329067)
1. Treatment Persistence of Infliximab Versus Adalimumab in Ulcerative Colitis: A 16-Year Single-Center Experience.
Pouillon L; Baumann C; Rousseau H; Choukour M; Andrianjafy C; Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2019 Apr; 25(5):945-954. PubMed ID: 30329067
[TBL] [Abstract][Full Text] [Related]
2. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
[TBL] [Abstract][Full Text] [Related]
3. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcome of adalimumab therapy in patients with ulcerative colitis previously treated with infliximab: a Danish single-center cohort study.
Christensen KR; Steenholdt C; Brynskov J
Scand J Gastroenterol; 2015 Aug; 50(8):1018-24. PubMed ID: 25861832
[TBL] [Abstract][Full Text] [Related]
5. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
Olivera P; Thiriet L; Luc A; Baumann C; Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2017 Jun; 23(6):976-985. PubMed ID: 28333755
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
[TBL] [Abstract][Full Text] [Related]
7. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
Ko Y; Paramsothy S; Yau Y; Leong RW
Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
[TBL] [Abstract][Full Text] [Related]
8. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.
Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1218-1225.e7. PubMed ID: 27913244
[TBL] [Abstract][Full Text] [Related]
10. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
[TBL] [Abstract][Full Text] [Related]
11. Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation.
Taxonera C; Iglesias E; Muñoz F; Calvo M; Barreiro-de Acosta M; Busquets D; Calvet X; Rodríguez A; Pajares R; Gisbert JP; López-Serrano P; Pérez-Calle JL; Ponferrada Á; De la Coba C; Bermejo F; Chaparro M; Olivares D; Alba C; Fernández-Blanco I
Dig Dis Sci; 2017 Feb; 62(2):481-490. PubMed ID: 27995400
[TBL] [Abstract][Full Text] [Related]
12. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
[TBL] [Abstract][Full Text] [Related]
13. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
Zhou Z; Dai C; Liu WX
Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
[TBL] [Abstract][Full Text] [Related]
14. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
15. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis.
Kobayashi T; Udagawa E; Uda A; Hibi T; Hisamatsu T
J Gastroenterol Hepatol; 2020 Feb; 35(2):225-232. PubMed ID: 31397010
[TBL] [Abstract][Full Text] [Related]
16. Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy.
Sartini A; Scaioli E; Liverani E; Bellanova M; Ricciardiello L; Bazzoli F; Belluzzi A
Dig Dis Sci; 2019 Mar; 64(3):863-874. PubMed ID: 30334112
[TBL] [Abstract][Full Text] [Related]
17. Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study.
Shin JY; Park HM; Lee MY; Jeon JY; Yoo HJ; Ye BD
Gut Liver; 2021 Nov; 15(6):867-877. PubMed ID: 33785664
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
[TBL] [Abstract][Full Text] [Related]
19. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy.
Mizoshita T; Katano T; Tanida S; Hirano A; Miyaki T; Ozeki K; Suzuki Y; Sugimura N; Kataoka H; Joh T
Medicine (Baltimore); 2017 Aug; 96(32):e7800. PubMed ID: 28796080
[TBL] [Abstract][Full Text] [Related]
20. Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.
Ananthakrishnan AN; Cagan A; Cai T; Gainer VS; Shaw SY; Savova G; Churchill S; Karlson EW; Kohane I; Liao KP; Murphy SN
Inflamm Bowel Dis; 2016 Apr; 22(4):880-5. PubMed ID: 26933751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]